CPRX.NASDAQCatalyst Pharmaceuticals, INC

Form 4: Catalyst Pharmaceuticals Director Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)

📋All filings for Catalyst Pharmaceuticals, INC
🔒Login to Follow

Patrick J Mcenany, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Summary

  • Disposition to the issuer: disposed of 4,171,559 Common Stock, par value $0.001 per share at $31.50 ($131,404,108) on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 740,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 400,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 270,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 272,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 73,810 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 43,591 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 34,921 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 3,534 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 3,552 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 10,540 Restricted Stock Units on July 15, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Patrick J Mcenany — Director, Other (Chairman of Board of Directors)

DateTransactionSecuritySharesPriceValueHeld After
2026-07-15Disposition to the issuerCommon Stock, par value $0.001 per share4,171,559$32$131.4M0
2026-07-15Disposition to the issuerOptions to purchase common stock740,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock400,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock270,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock272,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock73,810——0
2026-07-15Disposition to the issuerOptions to purchase common stock43,591——0
2026-07-15Disposition to the issuerOptions to purchase common stock34,921——0
2026-07-15Disposition to the issuerRestricted Stock Units3,534——0
2026-07-15Disposition to the issuerRestricted Stock Units3,552——0
2026-07-15Disposition to the issuerRestricted Stock Units10,540——0

Key Dates

DateDescription
2026-07-15Disposition to the issuer (4,171,559 shares)
2026-07-15Disposition to the issuer (740,000 shares)
2026-07-15Disposition to the issuer (400,000 shares)
2026-07-15Disposition to the issuer (270,000 shares)
2026-07-15Disposition to the issuer (272,000 shares)
2026-07-15Disposition to the issuer (73,810 shares)
2026-07-15Disposition to the issuer (43,591 shares)
2026-07-15Disposition to the issuer (34,921 shares)
2026-07-15Disposition to the issuer (3,534 shares)
2026-07-15Disposition to the issuer (3,552 shares)
2026-07-15Disposition to the issuer (10,540 shares)

Keywords

insider transaction, Form 4, CPRX, CATALYST PHARMACEUTICALS, INC., neutral, Patrick J Mcenany

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.